Remission of hepatotoxicity in chronic pulmonary aspergillosis patients after lowering trough concentration of voriconazole

Table 1 Demographic characteristics and efficacy in both groups of patients

Characteristics	Reduced-dose group, n = 12	Standard-doses group, n = 25	P value
Demographics
Age, median range	70.0 ± 15.8	62.8 ± 9.6	0.17
Male/female	8/4	17/8	1.00
Underlying diseases leading to CPA
Chronic obstructive pulmonary diseases	3	9	0.71
Tuberculosis sequelae	4	1	0.03
Bronchiectasis	4	8	1.00
Lung cancer survivor	0	2	1.00
Interstitial lung disease	5	3	0.83
Steroid therapy
Inhaled glucocorticoid	6	13	0.91
Oral glucocorticoid	7	16	1.00
Additional predisposing factors
Diabetes	2	3	1.00
Smoking	7	15	1.00
Laboratory test after treatment
CRP	5.1 ± 3.7	6.6 ± 5.1	0.38
ESR	24.3 ± 25.6	15.9 ± 15.0	0.31
Total immunoglobulin E	206.8 ± 269.9	279.7 ± 191.7	0.35
Trough plasma concentration	1.70 ± 0.78 µg/mL (0.6-3.3 µg/mL)	2.22 ± 0.94 µg/mL (0.8-4.1 µg/mL)	0.10
Therapeutic effect after 4 mo
Effective	5	8	0.72
Stable + failure	5 + 2	14 + 3

CPA: Chronic pulmonary aspergillosis; CRP: C-reaction protein; ESR: Erythrocyte sedimentation rate.